Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed.

Palumbo C, Battisti S, Carbone D, Albonici L, Alimandi M, Bei R, Modesti A.

Cancer Chemother Pharmacol. 2008 Apr;61(5):893-901. Epub 2007 Oct 6.

PMID:
17922127
2.

Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models.

LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX.

Mol Cancer Ther. 2006 Feb;5(2):347-55.

3.

No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo.

Sasaki Y, Kjellén E, Mineta H, Wennerberg J, Ekblad L.

Acta Oncol. 2009;48(7):1062-9. doi: 10.1080/02841860902913553.

PMID:
19412811
4.

Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.

Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R.

Cancer Chemother Pharmacol. 2008 Apr;61(4):549-58. Epub 2007 May 24.

PMID:
17522864
5.

Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.

Kim SH, Song YC, Kim SH, Jo H, Song YS.

Ann N Y Acad Sci. 2009 Aug;1171:642-8. doi: 10.1111/j.1749-6632.2009.04893.x.

PMID:
19723115
6.

Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.

Kitazono-Saitoh M, Takiguchi Y, Kitazono S, Ashinuma H, Kitamura A, Tada Y, Kurosu K, Sakaida E, Sekine I, Tanabe N, Tagawa M, Tatsumi K.

Oncol Rep. 2012 Jul;28(1):33-40. doi: 10.3892/or.2012.1799. Epub 2012 May 4.

PMID:
22562354
7.

Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.

Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G.

Int J Oncol. 2010 Aug;37(2):437-44.

PMID:
20596671
8.

Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro.

Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Inoue K, Mori K, Fujii H, Mano H, Odgerel T, Furukawa Y.

Oncol Res. 2006;16(2):85-95.

PMID:
16898269
9.

Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.

Cameron RB, Hou D.

J Thorac Cardiovasc Surg. 2013 Feb;145(2):496-504. doi: 10.1016/j.jtcvs.2012.10.042. Epub 2012 Nov 20.

10.

FDA drug approval summaries: pemetrexed (Alimta).

Hazarika M, White RM, Johnson JR, Pazdur R.

Oncologist. 2004;9(5):482-8. Review.

11.

Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.

Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L.

Clin Cancer Res. 2009 Apr 15;15(8):2818-28. doi: 10.1158/1078-0432.CCR-08-1579. Epub 2009 Apr 7.

12.

Absence of functional EpoR expression in human tumor cell lines.

Swift S, Ellison AR, Kassner P, McCaffery I, Rossi J, Sinclair AM, Begley CG, Elliott S.

Blood. 2010 May 27;115(21):4254-63. doi: 10.1182/blood-2009-10-248674. Epub 2010 Feb 2.

13.

Erythropoietin enhancement of rat pancreatic tumor cell proliferation requires the activation of ERK and JNK signals.

Bose C, Udupa KB.

Am J Physiol Cell Physiol. 2008 Aug;295(2):C394-405. doi: 10.1152/ajpcell.00423.2007. Epub 2008 Jun 11.

PMID:
18550701
14.

Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.

Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M.

Clin Cancer Res. 2009 Jan 1;15(1):382-9. doi: 10.1158/1078-0432.CCR-08-0128.

15.

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.

O'Kane SL, Eagle GL, Greenman J, Lind MJ, Cawkwell L.

Lung Cancer. 2010 Feb;67(2):160-5. doi: 10.1016/j.lungcan.2009.04.008. Epub 2009 May 17.

PMID:
19450893
16.

Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells.

Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ.

Prostate. 2006 Feb 1;66(2):135-45.

PMID:
16161153
17.

Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models.

Tóvári J, Gilly R, Rásó E, Paku S, Bereczky B, Varga N, Vágó A, Tímár J.

Cancer Res. 2005 Aug 15;65(16):7186-93.

18.

rHuEPO and treatment outcomes: the preclinical experience.

Ludwig H.

Oncologist. 2004;9 Suppl 5:48-54.

19.

Interferon-alpha and -gamma in combination with chemotherapeutic drugs: in vitro sensitivity studies in four human mesothelioma cell lines.

Hand AM, Husgafvel-Pursiainen K, Pelin K, Vallas M, Suitiala T, Ekman A, Mattson M, Mattson K, Linnainmaa K.

Anticancer Drugs. 1992 Dec;3(6):687-94.

PMID:
1288739
20.

Location and the functionality of erythropoietin receptor(s) in A2780 cells.

Solár P, Hrčková G, Varinská L, Solárová Z, Kriška J, Uhrínová I, Kello M, Mojžiš J, Fedoročko P, Sytkowski AJ.

Oncol Rep. 2012 Jul;28(1):141-6. doi: 10.3892/or.2012.1795. Epub 2012 Apr 30.

PMID:
22552716

Supplemental Content

Support Center